You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Johnson and Johnson
Baxter
AstraZeneca
Harvard Business School

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Evacetrapib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Evacetrapib?

Evacetrapib is an investigational drug.

There have been 21 clinical trials for Evacetrapib. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Hypercholesterolemia, Cardiovascular Diseases, and Hyperlipidemias. The leading clinical trial sponsors are Eli Lilly and Company, The Cleveland Clinic, and [disabled in preview].

There are five US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for Evacetrapib
TitleSponsorPhase
A Study of Different Particle Sizes of Evacetrapib in Healthy ParticipantsEli Lilly and CompanyPhase 1
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary HypercholesterolemiaEli Lilly and CompanyPhase 3
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy ParticipantsEli Lilly and CompanyPhase 1

See all Evacetrapib clinical trials

Clinical Trial Summary for Evacetrapib

Top disease conditions for Evacetrapib
Top clinical trial sponsors for Evacetrapib

See all Evacetrapib clinical trials

US Patents for Evacetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evacetrapib   Start Trial Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-be- nzazepin-1-yl]methyl]-cyclohexanecarboxylic acid Eli Lilly and Company (Indianapolis, IN)   Start Trial
Evacetrapib   Start Trial Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tet- razol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]met- hyl]-cyclohexanecarboxylic acid Eli Lilly and Company (Indianapolis, IN)   Start Trial
Evacetrapib   Start Trial Tetrazolones as a carboxylic acid bioisosteres Rigel Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
Evacetrapib   Start Trial Method of treating atherosclerosis in high triglyceride subjects NOVARTIS AG (Basel, CH)   Start Trial
Evacetrapib   Start Trial Dalcetrapib for therapeutic use Hoffmann-La Roche Inc. (Little Falls, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evacetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Evacetrapib Argentina 077208 2029-06-30   Start Trial
Evacetrapib Australia 2010266537 2029-06-30   Start Trial
Evacetrapib Brazil PI1011931 2029-06-30   Start Trial
Evacetrapib Canada 2764425 2029-06-30   Start Trial
Evacetrapib Chile 2011003263 2029-06-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Johnson and Johnson
Baxter
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.